Roth Capital Maintains Buy on Purple Innovation, Raises Price Target to $34
Roth Capital analyst Matt Koranda maintains Purple Innovation (NASDAQ:PRPL) with a Buy and raises the price target from $31 to $34.
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
54 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Purple Innovation Q2 Revenue Tops Estimate; Cuts FY21 Outlook Citing Production Issues
Purple Innovation Inc (NASDAQ:PRPL) reported second-quarter FY21 revenue growth of 10.6% year-on-year, to $182.6 million, beating the analyst consensus of $176.99…
8 Stocks Moving In Monday’s After-Hours Session
Gainers
Kansas City Southern (NYSE: KSU) shares are trading higher following a report suggesting Canadian Pacific plans a new higher bid for the company, near $300 per share.
Purple Innovation Q2 Adj. EPS $0.05 Up From $(0.11) YoY, Sales $182.60M Beat $176.99M Estimate
Purple Innovation (NASDAQ:PRPL) reported quarterly earnings of $0.05 per share. This is a 145.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of
Unusual Options Activity Insight: Purple Innovation
Purple Innovation (NASDAQ:PRPL) shares experienced unusual options activity on Monday. The stock price moved down to $25.1 following the option alert.
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
Roth Capital Maintains Buy on Purple Innovation, Lowers Price Target to $31
Roth Capital analyst Matt Koranda maintains Purple Innovation (NASDAQ:PRPL) with a Buy and lowers the price target from $37 to $31.